Found: 23
Select item for more details and to access through your institution.
Randomized, Blinded, Placebo- and Positive-Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 1, p. 22, doi. 10.1002/cpdd.352
- By:
- Publication type:
- Article
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 1, p. e12, doi. 10.1111/bjh.17999
- By:
- Publication type:
- Article
Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 6, p. 1031, doi. 10.1002/ajh.27276
- By:
- Publication type:
- Article
Efficacy and safety of early‐start deferiprone in infants and young children with transfusion‐dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double‐blind, placebo‐controlled, clinical trial (START)
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. 1415, doi. 10.1002/ajh.27010
- By:
- Publication type:
- Article
Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074414
- By:
- Publication type:
- Article
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 3, p. 533, doi. 10.1007/s00277-021-04728-0
- By:
- Publication type:
- Article
A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone.
- Published in:
- Annals of the New York Academy of Sciences, 1998, v. 850, n. 1, p. 223, doi. 10.1111/j.1749-6632.1998.tb10478.x
- By:
- Publication type:
- Article
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 4, p. 994, doi. 10.1111/bcp.13037
- By:
- Publication type:
- Article
Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
- Published in:
- European Journal of Haematology, 2014, v. 92, n. 4, p. 337, doi. 10.1111/ejh.12241
- By:
- Publication type:
- Article
Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Cost-Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 9, p. 807, doi. 10.1007/s40273-013-0076-z
- By:
- Publication type:
- Article
Deferiprone in Friedreich ataxia: A 6-Month randomized controlled trial.
- Published in:
- Annals of Neurology, 2014, v. 76, n. 4, p. 509, doi. 10.1002/ana.24248
- By:
- Publication type:
- Article
Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.
- Published in:
- PLoS ONE, 2016, v. 11, n. 5, p. 1, doi. 10.1371/journal.pone.0154842
- By:
- Publication type:
- Article
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
- Published in:
- Pediatric Blood & Cancer, 2024, v. 71, n. 1, p. 1, doi. 10.1002/pbc.30711
- By:
- Publication type:
- Article
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 5, p. 879, doi. 10.1002/pbc.24920
- By:
- Publication type:
- Article
Rational Design of Novel Therapies for Pantothenate Kinase–Associated Neurodegeneration.
- Published in:
- Movement Disorders, 2021, v. 36, n. 9, p. 2005, doi. 10.1002/mds.28642
- By:
- Publication type:
- Article
Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion‐dependent thalassemia: A randomized controlled trial.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. 262, doi. 10.1002/ajh.24966
- By:
- Publication type:
- Article
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 10, p. 1026, doi. 10.1002/ajh.24479
- By:
- Publication type:
- Article
Iron overload in Brazilian thalassemic patients.
- Published in:
- Einstein (16794508), 2011, v. 9, n. 2, p. 165, doi. 10.1590/s1679-45082011ao1897
- By:
- Publication type:
- Article
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 1, p. 330, doi. 10.1046/j.1365-2141.2002.03554.x
- By:
- Publication type:
- Article
G6PD 'campinas:' A deficient enzyme with a mutation at the far 3′ end of the gene.
- Published in:
- Human Mutation, 1993, v. 2, n. 1, p. 77, doi. 10.1002/humu.1380020115
- By:
- Publication type:
- Article
Updates in Hemoglobinopathies.
- Published in:
- Scientific World Journal, 2013, p. 1, doi. 10.1155/2013/912913
- By:
- Publication type:
- Article